GlassScriptPhysician profile
Stuart G Mendelson
NPI 1932175411
$2,924.39
in general payments reported to CMS, 2019-2025
16 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $323 · 2021: $124 · 2022: $478 · 2023: $609 · 2024: $485 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.23 | 2021-2025 | |
| Amgen INC. | $325.40 | 2019-2025 | Uplizna |
| Lilly USA, LLC | $317.64 | 2019-2024 | Kisunla |
| Biogen, INC. | $226.46 | 2019-2022 | |
| Acorda Therapeutics, INC | $213.41 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $212.68 | 2022-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $185.89 | 2022 | |
| Microtransponder, INC. | $138.97 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $133.28 | 2022 | |
| Celgene Corporation | $129.12 | 2023 | Zeposia |
| Neurocrine Biosciences, INC. | $127.46 | 2023 | Ongentys, Ingrezza |
| Argenx US, INC. | $125.00 | 2025 | Vyvgart Hytrulo |
| Eisai INC. | $119.26 | 2024 | |
| Azurity Pharmaceuticals, INC. | $107.57 | 2023 | Horizant |
| Genentech USA, INC. | $107.00 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Mendelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.